The placebo-controlled, double-blind, randomized clinical trial (RCT) holds unique advantages for evaluating medical technologies, and figures prominently in clinical drug investigations. However, medicine, like other social sectors, has experienced a movement toward evidence-based practice and policy decision-making that involves the evaluation of complex non-pharmacological interventions that frequently challenge the use of the RCT. Even with pharmaceuticals used in clinical practice, the application of RCTs has its limitations and challenges. This paper argues that both the modality of therapy (drugs, devices, and procedures) and the stage of technological evolution are important determinants of an optimal evaluative design. The practicality of conducting an RCT is inversely proportional to the complexity of the healthcare intervention. Iterative modifications of medical devices, provider-specific practices, and an evolving clinical knowledge-base are just some of the problems plaguing technology assessments. Lessons learned on the role of randomized versus observational study designs may prove valuable for other social sectors.
Download Info
To download:
If you experience problems downloading a file, check if you have the
proper application to
view it first. Information about this may be contained
in the File-Format links below. In case of further problems read
the IDEAS help
file. Note that these files are not on the IDEAS
site. Please be patient as the files may be large.
As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.